April 30 (SeeNews) - North Macedonia-based drug maker Replek [MSE:REPL] said on Tuesday that its consolidated net profit rose 21% year-on-year to 22.9 million denars ($398,368/371,899 euro) in the first quarter of 2024.
Replek's operating revenue rose 25% on the year to 395.2 million denars in January-March, whereas operating costs were 33% higher at 383.5 million denars, the company said in an interim financial statement filed with the Skopje bourse.
Sales revenues from the domestic market gained 39% on an annual comparison basis, reaching 75.7 million denars in the first quarter. Sales revenues from abroad increased 23% to 312.2 million denars.
Replek's shares last traded at an average price of 109,000 denars on the Macedonian Stock Exchange (MSE) on April 26, according to the latest available bourse data.
(1 euro = 61.58 denars)